Show simple item record

dc.identifier.uri http://dx.doi.org/10.15488/799
dc.identifier.uri http://www.repo.uni-hannover.de/handle/123456789/823
dc.contributor.author Seleci, Didem Ag
dc.contributor.author Seleci, Muharrem
dc.contributor.author Jochums, André
dc.contributor.author Walter, Johanna-Gabriela
dc.contributor.author Stahl, Frank
dc.contributor.author Scheper, Thomas
dc.date.accessioned 2016-12-06T07:33:04Z
dc.date.available 2016-12-06T07:33:04Z
dc.date.issued 2016
dc.identifier.citation Seleci, Didem Ag; Seleci, Muharrem; Jochums, André; Walter, Johanna-Gabriela; Stahl, Frank et al.: Aptamer mediated niosomal drug delivery. In: RSC Advances 6 (2016), Nr. 91, S. 87910-87918. DOI: http://dx.doi.org/10.1039/C6RA19525C
dc.description.abstract Development of nanoscale carrier systems for targeted drug delivery is crucial for cancer treatment. The current methods of drug delivery exhibit some problems such as lack of therapy efficiency at the desired parts of the body, degradation of the drug before reaching the desired tissue and limitations in cellular penetration. In this work, a novel drug delivery platform was developed to overcome these problems and to enable specific and efficient uptake into the cells. The surface of the synthesized polyethylene glycolated niosomes (PEGNIO) was modified with cell penetrating peptide (CPP) and cell specific MUC1 (S2.2) aptamer, and doxorubicin (DOX) as a cancer model drug was encapsulated in this platform. Fluorescence microscopy and flow cytometry analysis were used to investigate the cellular uptake and intracellular distribution of the DOX loaded niosomal formulation. In vitro cytotoxicity studies were carried out using MUC1 positive HeLa and negative U87 cells. Moreover, dynamic light scattering (DLS), zeta potential measurements and fluorescence absorption spectroscopy were performed to determine the vesicle size, as well as charge and spectroscopic properties of the conjugates. From these results, this novel aptamer mediated niosomal drug delivery platform may have application potential in targeted drug delivery towards MUC1-overexpressing tumors. eng
dc.description.sponsorship Konrad Adenauer Foundation
dc.language.iso eng
dc.publisher Cambridge : Royal Society of Chemistry
dc.relation.ispartofseries RSC Advances 6 (2016), Nr. 91
dc.rights CC BY 3.0
dc.rights.uri https://creativecommons.org/licenses/by/3.0/
dc.subject nanoscale carrier systems eng
dc.subject PEGNIO eng
dc.subject cell penetrating peptide (CPP) eng
dc.subject polyethylene glycolated niosomes eng
dc.subject.ddc 540 | Chemie ger
dc.title Aptamer mediated niosomal drug delivery
dc.type article
dc.type Text
dc.relation.essn 2046-2069
dc.relation.doi http://dx.doi.org/10.1039/C6RA19525C
dc.bibliographicCitation.issue 91
dc.bibliographicCitation.volume 6
dc.bibliographicCitation.firstPage 87910
dc.bibliographicCitation.lastPage 87918
dc.description.version publishedVersion
tib.accessRights frei zug�nglich


Files in this item

This item appears in the following Collection(s):

Show simple item record

 

Search the repository


Browse

My Account

Usage Statistics